ANTI CCL2 AND ANTI LOXL2 COMBINATION THERAPY FOR TREATMENT OF SCLERODERMA

摘要

The present invention provides, among other things, bi-specific molecules including, but not limited to, antibodies, fynomers, aptamers, fusion proteins, and protein binding domains that bind both CCL2 and LOXL2 and uses thereof, in particular, for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions. In some embodiments, the present invention further provides methods and compositions for treatment of scleroderma and related fibrotic and/or inflammatory dis eases, disorders and conditions based on the combination of mono-specific anti-CCL2 and anti-LOXL2 molecules.